4 citations
,
May 2020 in “Dermatologic Therapy” Redenyl lotion effectively promotes hair growth and improves quality of life for androgenetic alopecia patients.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
7 citations
,
August 2020 in “Majalah Farmasetika” A herbal hair tonic with 2.5% green tea extract is most effective for hair growth.
1 citations
,
December 2023 in “Plastic Surgery” Tissue expansion surgery generally improves quality of life in children, especially for scars and alopecia.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
Telogen Effluvium causes increased hair shedding and can be challenging to diagnose and treat.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The body can heal and achieve remarkable states through specific mind-body practices.
September 2023 in “Journal of the American Academy of Dermatology”
September 2013 in “Metal Powder Report” Dynamet Technology won an award for its advanced titanium technology.
January 1985 in “Clinical research” Topical alpha-terthienyl with UVA may safely treat psoriasis without cancer risk.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The "Danti Original Source" method can reverse androgenetic alopecia.
September 2025 in “Immunological Reviews” The skin can independently form immune responses through special structures, offering new ways to treat skin diseases.
Low ferritin and vitamin D levels are linked to hair loss.
September 2025 in “Stem Cell Research & Therapy” TAZ boosts fat cell formation in goat stem cells by activating a specific signaling pathway.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
6 citations
,
January 2018 in “PubMed” Heavy metals might contribute to hair loss in Telogen Effluvium.
15 citations
,
February 2015 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Dermoscopy helps accurately diagnose temporal triangular alopecia, avoiding unnecessary treatments.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
August 2024 in “International Journal of Health Science” Telogen Effluvium (TE) significantly affects women due to stress and hormonal changes, requiring better public health policies and mental health support.
March 2026 in “Skin Appendage Disorders” Telogen effluvium is linked to low ferritin and vitamin D levels.
6 citations
,
March 2022 in “Molecules” Methyl jasmonate boosts tanshinone production in Salvia miltiorrhiza callus cultures.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
January 2026 in “Journal of Materials Chemistry B” TA-Ado effectively promotes hair growth and reduces hair loss.
March 2026 in “Journal of the European Academy of Dermatology and Venereology” VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.
December 2025 in “Journal of Paediatrics and Child Health” Tick-bite alopecia can be identified by a bite-centered mark and treated with topical steroids, while SENLAT needs doxycycline.
June 1992 in “The Journal of dermatologic surgery and oncology”